TY - JOUR
T1 - Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy
AU - Alenkina, Irina V.
AU - Chukin, Andrey V.
AU - Leitus, Gregory
AU - Denisova, Olga V.
AU - Gracheva, Maria
AU - Felner, Israel
AU - Kuzmann, Ernő
AU - Homonnay, Zoltán
AU - Oshtrakh, Michael I.
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2024/1/5
Y1 - 2024/1/5
N2 - Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.
AB - Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.
KW - Iron state, Mössbauer spectroscopy
KW - Iron-containing pharmaceuticals
KW - Magnetization measurements
KW - X-ray diffraction
UR - http://www.scopus.com/inward/record.url?scp=85173271405&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2023.115745
DO - 10.1016/j.jpba.2023.115745
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37832473
AN - SCOPUS:85173271405
SN - 0731-7085
VL - 237
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
M1 - 115745
ER -